Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis

Debanjali Mitra1*, Paul Hodgkins2, Linnette Yen2, Keith L Davis1 and Russell D Cohen3

Abstract

Background: Observational cohort study to assess the association between adherence to oral 5-aminosalicylates (5-ASAs) and all-cause costs and health care utilization among patients with active ulcerative colitis (UC) in the United States.

Methods: Retrospective analysis of insurance claims from June 1997 to August 2006 in the LifeLink Database. Patient criteria: aged 18 or older with one or more claim(s) between June 1997 and August 2005 for a UC diagnosis and at least one oral 5-ASA prescription on or after the first observed UC diagnosis; continuous enrollment for at least 6 months prior to and 12 months following 5-ASA initiation (index date). As a proxy for active disease, patients needed to have at least two UC-specific non-pharmacy claims, at least 30 days of 5-ASA treatment and at least one corticosteroid prescription within the 12-month post-index period. Cumulative exposure to oral 5-ASAs over the 12-month period was calculated using the medication possession ratio (MPR). Patients with an MPR of at least 0.80 were classified as adherent. All-cause medical and pharmacy resource utilization and costs were computed over the 12-month post-index period and compared between adherent and nonadherent patients.

Results: 1,693 UC patients met study inclusion criteria: 72% were nonadherent to 5-ASA treatment (n = 1,217) and 28% were adherent (n = 476) in the 12-month study period. Compared with nonadherent patients, adherent patients had 31% fewer hospitalizations (P = 0.0025) and 34% fewer emergency department admissions (P = 0.0016). Adherent patients had 25% more pharmacy prescriptions overall (P <0.0001) and 71% more UC-related pharmacy prescriptions (P <0.0001) than did nonadherent patients. Total all-cause health care utilization was 1.13 times higher for adherent patients than for nonadherent patients (P = 0.0002). After adjusting for covariates, total all-cause costs were 29% higher for nonadherent patients than for adherent patients (mean [95% confidence interval]: $13,465 [$13,094, $13,835] vs $17,339 [$17,033, $17,645]).

Conclusions: Approximately three-quarters of patients with active UC were not adherent with their prescribed doses of oral 5-ASA. Nonadherence was associated with higher total all-cause costs. The key driver of decreased costs among adherent patients was inpatient hospitalizations, which more than offset these patients’ expected higher pharmacy costs.

* Correspondence: mitra@rti.org

1RTI Health Solutions, 3040 Cornwallis Road, Post Office Box 12194, Research Triangle Park, NC 27709-2194, USA

Full list of author information is available at the end of the article

© 2012 Mitra et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by mucosal inflammation in the colon. Usually, UC affects individuals between 15 and 40 years of age, although it can be found among patients of any age. The annual incidence rate of UC in the United States (US) is estimated to be eight cases per 100,000 individuals[1]. UC is an expensive medical condition, imposing a significant burden on patients, employers, and third-party payers. In 1998, the total direct cost of UC in the US was estimated to be $388 million, with pharmacotherapy contributing to $138 million of these costs and inpatient hospitalizations accounting for 50% of the total expenditure [2]. The reported annual direct economic burden per patient varies significantly in the literature. Kappleman et al., [3] using an administrative claims data set, found the mean annual direct health care cost of UC to be $5,066 per patient per year (in 2004 US dollars); 38% of costs were attributable to hospitalization, 35% to outpatient care, and 27% to pharmaceutical claims. Another study found the mean annual all-cause total health care costs for patients with UC to be $13,233 (in 2005 US dollars), 44% of which consisted of inpatient hospitalization costs [4].

Because the underlying cause is usually unclear, treatment of UC is typically aimed at first controlling inflammation and symptoms (i.e., inducing remission) and then maintaining that control (i.e., maintaining remission) [5,6]. According to the American College of Gastroenterology practice guidelines for adult UC patients, [7] oral therapy with 5-aminosalicylic acids (5-ASAs) such as mesalamine, balsalazide, sulfasalazine, and olsalazine is typically used as first-line therapy for mild to moderate UC. Therapy with 5-ASAs has been shown to be efficacious and well tolerated both for the treatment of active disease [6] and for the maintenance of remission [5]. However, some of the current oral formulations of 5-ASAs are inconvenient for patients because patients require multiple doses per day and/or multiple tablets per dose. In a chronic disease such as UC, where patients may be on long-term or lifelong medication support, such treatment imposes a significant burden on UC patients, and potentially can reduce quality of life and can negatively impact adherence to the treatment. Previous studies have found that, for the patient being treated for a chronic condition, nonadherence to the treatment can cause a reduction in treatment benefits, [8] can bias clinician assessment of the treatment’s effectiveness, [9] and can lead to poorer disease prognosis [10]. Further, nonadherence to treatment for chronic conditions has been linked to increased health care utilization [11].

Previous studies have demonstrated that adherence and persistence with 5-ASAs in patients with UC is usually low. In a study using the IMS LifeLink database (IMS Health Incorporated, Danbury, Connecticut; formerly PHARMetrics Inc.), Yen et al. [12] found that only 15.2% of patients were adherent to oral 5-ASA therapy in the first year following treatment initiation. Another study found that among patients receiving pharmacotherapy for gastrointestinal conditions, only 22% were persistent with their oral 5-ASA therapy [13]. In a review article on adherence to UC therapy, Kane[14] concluded that failure to adhere to the prescribed UC regimen is associated with an increased risk of symptomatic relapse, greater risk of disease progression (e.g., development of colorectal cancer), decreased quality of life, and higher overall cost of care. Improving medication adherence in UC patients therefore could lead to reduced health care costs and improved outcomes.

Although the significant economic burden of UC and the low rate of adherence with UC medications has been well established in the literature, the impact of adherence with oral 5-ASA therapies on health care utilization and associated costs among patients with active UC has not been widely investigated. In this study, we analyzed administrative claims data from a large managed care population in the US to examine the impact of oral 5-ASA adherence on all-cause health care utilization and costs (both medical and pharmacy) among adult patients with evidence of active UC.

Methods
Data source
Data were extracted from the IMS LifeLink database. At the time of our study, the database included enrollment, medical, and prescription information from 75 managed care health plans covering more than 40 million unique patients and over 2 billion health care transactions in the US from 1997 to 2006. The LifeLink database comprises longitudinal insurance claims from managed care organizations in all four US geographic regions and has an age and gender distribution representative of national managed care enrollment [15].

The LifeLink database consists of patient demographics, institutional and professional medical claims for inpatient and outpatient services, outpatient prescription drug claims, and periods of health plan enrollment (start and stop dates). Each medical claim includes date and place of service (e.g., inpatient, outpatient, emergency department [ER]), four International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis codes, and cost data in the form of managed care reimbursements (actual paid amount) for medical services and prescription drugs utilized. Medical claims in the database also include Health Care Financing Administration Common Procedure Coding System and Current Procedural Terminology Version 4.
codes indicating the type of procedure (if any) provided, as well as information on provider specialty. Prescription drug claims include the National Drug Code, brand and generic name, quantity dispensed, days’ supply, strength, and paid amount for prescriptions obtained through outpatient or retail pharmacies. Data are tracked longitudinally within patients via de-identified and unique patient numbers.

Due to the de-identified nature of the LifeLink database and the fact that no new data were gathered, our study was granted exemption from the Institutional Review Board at RTI International, which holds a Federal-Wide Assurance (#3331) from the US Department of Health and Human Services’ Office for Human Research Protections; RTI Health Solutions, the organization that conducted this study, is a business unit of RTI International.

Study population
Our study sample was defined by selecting patients from the LifeLink database (1997–2006) who had any primary or nonprimary diagnosis of UC (ICD-9-CM 556.xx) between June 1997 and August 2005 and at least one prescription claim for an oral 5-ASA on or after the date of each patient’s first observed UC diagnosis. For each patient identified, an index date was defined as the date of the first observed prescription for an oral 5-ASA. To ensure that each patient’s index date was a reasonable marker for oral 5-ASA therapy initiation (or re-initiation after an extended break), patients included in the study sample were required to have at least 6 months of continuous health plan enrollment prior to their index date, with no evidence of 5-ASA use during that time frame.

Similarly, to ensure that any observed lack of health care events following 5-ASA therapy initiation was due to a true lack of medical activity and not cessation of insurance, patients included in the study sample were required to have at least 12 months of medical and pharmacy benefits eligibility following their index date. Each patient also was required to have a minimum duration of 30 days of 5-ASA therapy during the 12-month follow-up period. Finally, patients were required to have at least one period of active disease during follow-up, which was identified by proxy as evidence of of at least two UC-specific non-pharmacy claims and at least one corticosteroid prescription within the 12-month post-index date period. Patients with Crohn’s disease (ICD-9-CM 555.xx) were excluded from the study.

Study measures
Baseline patient characteristics
Patient characteristics that were measured at the index date included age, gender, geographic region, insurance payer type (e.g., commercial, self, government sponsored), and health plan type (e.g., health maintenance organization, preferred provider organization). To assess overall comorbidity burden prior to 5-ASA initiation, a Charlson Comorbidity Index (CCI) score, with Deyo adaptation for claims data, was calculated for each patient [16,17]. The CCI includes 17 categories of comorbidities, as defined by ICD-9-CM diagnosis codes, with associated weights corresponding to the severity of the comorbid condition of interest. A higher CCI score represents a higher overall comorbidity burden. A single CCI score was calculated for each patient on the basis of the presence of the corresponding diagnosis during the 6-month period prior to the index date.

Adherence measure
Oral 5-ASA adherence was measured using the medication possession ratio (MPR). A systematic literature review [18] found the MPR to be the most widely adopted measure (57% of all studies) in published claims-based analyses of medication adherence. MPR is defined as the proportion of days within an observation period covered by the total days’ supply for a particular study drug within the observation period. The observation period used in the MPR calculation can be either a fixed number of days within a follow-up period (i.e., 365 days following treatment initiation) or the number of days between the first dispense date and end of the days’ supply of the last refill for the study therapy of interest [18]. Oral 5-ASAs are intended to be used continuously and long-term (i.e., chronically) in order to maintain remission. Therefore, adherence for these medications must be evaluated with respect to drug exposure or supply coverage over a longer, fixed period. In this context, early discontinuation would count against MPR, and the use of a denominator that is defined as days between the first dispense and last prescription dates does not capture the negative adherence effect of complete therapy discontinuation.

To account for discontinuation, we defined the denominator of the MPR formula as a fixed value of 365 days (i.e., total days in the fixed, post-index follow-up period) so that those patients who discontinued 5-ASA therapy completely before the end of the follow-up period would correctly have a lower MPR. The following formula was used:

\[
\text{MPR} = \frac{\text{Total oral 5-ASA days supplied}}{\text{in 12-month follow-up period}} \div 365 \text{ days}.
\]

Note that changes in medication dose had no impact on how refill adherence was calculated. A patient who had a dose titration upward or downward would have the same adherence as a patient who remained on the
same dose, as long as both patients had identical prescription refill patterns. Mean MPR and adherence rates were calculated for the overall 5-ASA class, not separately by individual 5-ASA medications. For example, if a patient switched from mesalamine to sulfasalazine, the patient’s adherence was measured as cumulative exposure to both 5-ASA drugs. Switching between two oral 5-ASA classes therefore did not impact the calculation of MPR.

Patients with an MPR of less than 0.8 (i.e., less than 80% adherence) were classified as nonadherent. The 80% threshold for identifying adherence and nonadherence to chronic-use medications has been previously validated [19] and has been used in numerous previously conducted adherence studies [20-22]. To assess the distribution of MPR among nonadherent patients, patients with an MPR of less than 0.8 were further stratified into four groups: MPR 0.0 to 0.19, 0.20 to 0.39, 0.40 to 0.59, and 0.60 to 0.79.

**All-cause health care utilization and costs**

Total health care services utilized and associated costs during the 12-month period following initiation of 5-ASA therapy were calculated. Costs were calculated from the perspective of the third-party payer and represented actual reimbursed amounts for each service rendered. Our cost data therefore did not take into account patient copayments, co-insurance, and other out-of-pocket expenses. All-cause health care utilization and costs were compared between the group of patients who were adherent to 5-ASA therapy and the group of patients who were not. Differences in baseline demographic characteristics (age, gender, geographic region, health plan type, and payer type) and comorbidity burden (CCI scores) were controlled for when calculating total adjusted all-cause health care utilization. We did not adjust for baseline, i.e., pre-index, health care costs. The adjusted all-cause health care costs were stratified by the following cost sectors: inpatient admissions, ER visits, outpatient office visits, other non-office outpatient/ancillary visits (e.g., day procedures), and prescription drugs (UC related and non-UC related). UC-related prescriptions were defined as all prescriptions for oral and rectal 5-ASAs, corticosteroids, biologics (infliximab), immunosuppressants, and select antibiotics (ciprofloxacin and metronidazole). All cost estimates were adjusted to 2010 US dollars, using the medical care component of the US Consumer Price Index [23].

**Statistical analyses**

All analyses were carried out using SAS (Version 9.1.3) statistical software package (SAS Institute, Inc, Cary, North Carolina). Descriptive analyses entailed the tabular display of the mean value, standard deviation, median, and range of continuous variables of interest and the frequency distribution of categorical variables of interest. For descriptive analyses, chi-squared tests for dichotomous variables and paired t-tests for continuous variables were used to assess statistical differences in the outcomes of interest across all patients, stratified by adherence status.

Multivariable regression analyses were performed to assess differences in all-cause health care utilization and costs between 5-ASA adherent and nonadherent UC patients after controlling for patient demographic characteristics and baseline comorbidity burden. The type of multivariable model estimated depended on the nature of the outcome that was assessed. For count data, outcomes such as number of inpatient admissions and outpatient office visits were used. Poisson regression models were used to compare the rate of resource utilization between the two study cohorts. These models provided incidence rate ratios (IRRs), which were obtained by exponentiating the coefficients from each model estimated. The magnitude of the IRR describes the incidence rate of utilization (e.g., number of hospitalizations) for patients adherent to 5-ASA therapy as a multiple of the utilization incidence rate among nonadherent patients. For example, an estimated IRR of 0.5 for a binary covariate defining nonadherence (i.e., 1 = adherent, 0 = nonadherent) suggests that patients who were adherent with 5-ASA therapy had 50% fewer hospitalizations than patients who were nonadherent to 5-ASA therapy.

To assess differences in health care costs between the two study cohorts, a multivariable generalized linear model (GLM) framework was used, with a log-link function and a gamma distribution for the error term to resolve the issue of skewed cost distribution often reported in health care cost data. In comparison with ordinary linear regression involving log-transformed cost data, the GLM methodology offers several advantages, primarily because it estimates covariate-adjusted predicted mean costs on a dollar scale, which can then be compared using Student’s t-test [24-26]. The GLM methodology avoids potential biases resulting from the Duan smearing method for retransforming the predicted coefficient from log-transformed cost data [26-28].

**Results**

We identified 99,842 patients in the LifeLink database who had at least one primary or nonprimary diagnosis code for UC (ICD-9-CM 556.xx) between June 1997 and August 2005. Nearly 60% of these patients (n = 57,971) did not have any pharmacy claims for oral 5-ASA therapy and therefore were excluded. The final study sample consisted of 1,693 patients who met all study inclusion and exclusion criteria. Figure 1 provides a detailed breakdown of the sample attrition.
Demographic characteristics

Table 1 presents descriptive statistics on various baseline demographic characteristics of the study sample, overall and stratified by the adherence status. The mean age was 42 years for the overall study sample, and there was equal distribution of male and female patients. Nearly 45% of patients resided in the Midwest, with the remaining patients equally distributed between the East, South, and West. Preferred provider organizations and health maintenance organizations were the most common types of health plans, covering 40% and 37% of patients, respectively. The mean CCI score for the overall study sample was 1.23.

A slightly larger percentage of patients in the adherent group resided in the Midwest than did the nonadherent group (49% vs 43%; \(P = 0.0113\)). Further, adherent patients had a greater baseline comorbidity than did non-adherent patients (CCI score 1.36 vs 1.18; \(P = 0.0378\)).

Adherence measure

Figure 2 presents the overall MPR distribution for oral 5-ASA therapy. Twenty-eight percent of the sample was adherent to therapy over the 12-month follow-up period, while 20% of patients had an MPR less than 0.20. The mean MPR for the overall study sample was 0.54 (range: 0.08-1.00; median = 0.56; data not shown). Among the adherent group, the mean MPR was 0.90 (range: 0.80-1.00; median = 0.90); and among the nonadherent group, the mean MPR was 0.40 (range: 0.08-0.79; median = 0.38).
### Table 1 Characteristics of the study population, by 5-ASA adherence status

| Characteristic           | All 5-ASA Initiators | 5-ASA Initiators Adherence Status | P Value* |
|--------------------------|-----------------------|-----------------------------------|----------|
|                          | n (row%)              | Not Adherent % | Adherent % |
| Gender                   | 1693                  | 1217              | 476       |
| Female                   | 840                   | 628               | 212       | 0.0090 |
| Male                     | 853                   | 589               | 264       |        |
| Age                      |                       |                   |           |        |
| Mean (SD)                | 42.3 (12.8)           | 42.4 (12.8)       | 42.2 (12.9)| 0.7675 |
| Median                   | 42                    | 42                | 43.5      |        |
| Range (minimum, maximum) | (18, 93)              | (18, 93)          | (18, 78)  |        |
| Distribution (years)     |                       |                   |           |        |
| 18-24                    | 165                   | 112               | 53        | 0.2283 |
| 25-44                    | 775                   | 576               | 199       | 0.0403 |
| 45-54                    | 433                   | 304               | 129       | 0.3684 |
| 55-64                    | 280                   | 191               | 89        | 0.1349 |
| 65+                      | 40                    | 34                | 6         | 0.0619 |
| Geographic region        |                       |                   |           |        |
| East                     | 354                   | 260               | 94        | 0.4623 |
| Midwest                  | 759                   | 528               | 231       | 0.0113 |
| South                    | 306                   | 238               | 68        | 0.0557 |
| West                     | 274                   | 191               | 83        | 0.3815 |
| Health plan type         |                       |                   |           |        |
| HMO                      | 629                   | 442               | 187       | 0.2561 |
| Indemnity                | 39                    | 30                | 9         | 0.4788 |
| POS                      | 261                   | 181               | 80        | 0.3218 |
| PPO                      | 681                   | 505               | 176       | 0.0881 |
| Unknown                  | 30                    | 21                | 9         | 0.8168 |
| Multiple types           | 53                    | 38                | 15        | 0.9756 |
| Payer type               |                       |                   |           |        |
| Commercial               | 1423                  | 1020              | 403       | 0.6672 |
| Medicaid                 | 18                    | 15                | 3         | 0.2774 |
| Medicare                 | 48                    | 40                | 8         | 0.0735 |
| Self-insured             | 56                    | 37                | 19        | 0.3251 |
| Medigap                  | 2                     | 2                 | 0         | 0.3762 |
| Unknown                  | 144                   | 101               | 43        | 0.6262 |
| Multiple types           | 2                     | 2                 | 0         | 0.3762 |
| CCI score                |                       |                   |           |        |
| Mean (SD)                | 1.23 (1.60)           | 1.18 (1.59)       | 1.36 (1.62)| 0.0378 |
| Median                   | 0                     | 0                 | 0         |        |
| Range (minimum, maximum) | (0, 9)                | (0, 9)            | (0, 8)    |        |

5-ASA = 5-aminosalicylate; CCI = Charlson Comorbidity Index; HMO = health maintenance organization; POS = point of service; PPO = preferred provider organization; SD = standard deviation.

*Chi-square tests for categorical variables, t-tests for continuous variables.
Adjusted health care utilization and costs
Table 2 presents covariate-adjusted IRRs and corresponding 95% confidence intervals (CIs) from the Poisson regression models. The models were used to assess differences in the rate of all-cause health care resource utilization between the adherent and nonadherent patient cohorts. Adherent patients had approximately 31% (IRR = 0.6928; \( P = 0.0025 \)) fewer hospitalizations and 34% (IRR = 0.6584; \( P = 0.0016 \)) fewer ER admissions than did nonadherent patients. Patients who were adherent had 25% more pharmacy prescriptions overall. Adherent patients also had 71% more UC-related pharmacy prescriptions than did nonadherent patients, but the number of non–UC-related prescriptions did not differ between the two groups. The total number of all-cause health care visits across all cost sectors (including inpatient, ER, outpatient, and pharmacy) was 1.13 times higher for adherent patients than for nonadherent patients (IRR = 1.1294; \( P = 0.0002 \)).

Table 3 presents covariate adjusted predicted mean all-cause health care costs for adherent and nonadherent patients using GLM models. After adjusting for baseline demographic characteristics and the CCI score, the predicted mean all-cause cost per patient for hospitalizations was approximately two times higher for nonadherent patients than it was for adherent patients (mean [95% CI]: $14,542 [$14,314, $14,770] vs $28,727 [$28,443, $29,010]). The mean total cost of ER visits per patient was approximately 28% higher in the nonadherent group than in the adherent group. The mean costs of UC-related pharmacy prescriptions were more than two times higher for patients who were adherent than for those who were not (mean [95% CI]: $3,569 [$3,520, $3,617] vs $1,718 [$1,703, $1,734]). Total all-cause costs...

![Figure 2 MPR distribution for overall oral 5-ASA therapy.](http://www.biomedcentral.com/1471-230X/12/132)

**Table 2 Association between 5-ASA adherence and all-cause health care utilization during 12-month period following 5-ASA initiation**

| Dependent Variable                          | Incident Rate Ratio | Confidence Interval | P Value |
|---------------------------------------------|---------------------|---------------------|---------|
| Number of inpatient admissions              | 0.6928              | 0.5461              | 0.8789  | 0.0025 |
| Number of ER visits                         | 0.6584              | 0.5077              | 0.8538  | 0.0016 |
| Number of outpatient office visits          | 1.0004              | 0.9200              | 1.0878  | 0.9925 |
| Number of other outpatient/ancillary visits | 0.9306              | 0.8587              | 1.0086  | 0.0798 |
| Number of pharmacy prescriptions            | 1.2503              | 1.1624              | 1.3448  | <.0001 |
| Number of UC-related pharmacy prescriptions | 1.7095              | 1.6258              | 1.7974  | <.0001 |
| Number of non-UC-related pharmacy prescriptions | 0.9989              | 0.8862              | 1.1258  | 0.9852 |
| Number of non-pharmacy visits               | 0.9605              | 0.8937              | 1.0322  | 0.2725 |
| Number of total visits                      | 1.1294              | 1.0595              | 1.2039  | 0.0002 |

5-ASA = 5-aminosalicylate; ER = emergency department; UC = ulcerative colitis.

*Incident rate ratios are based on Poisson regression models and show utilization among adherent patients compared to nonadherent patients. All models control for age, gender, geographic region, health plan type, payer type, and Charlson Comorbidity Index scores.
health care costs, including all cost sectors, were about 29% higher for nonadherent patients than for adherent patients (mean [95% CI]: $17,339 [$17,033, $17,645] vs. $13,465 [$13,094, $13,835]). It must be noted that although GLM is a widely used tool to estimated adjusted costs, the predicted cost estimates for any particular cost sector were based on patients with at least one visit in that sector. For example, the mean predicted inpatient costs for the patient cohort were calculated among those patients who had an inpatient visit. This resulted in the mean inpatient costs for patients being much higher than the overall costs for all visits.

### Discussion

In this study, we examined the association between adherence to 5-ASA therapy and overall health care utilization and costs among patients with active UC. We estimated that only 28% of the UC patients on 5-ASAs who were included in the study were adherent to treatment. This finding was consistent with previous studies that have found adherence with 5-ASAs to be fairly low (range: 15%[12] to 22%[13]). We also found that adherence to oral 5-ASAs generally appeared to be associated with decreased health care utilization and costs, especially the rate of inpatient and ER admissions, despite the fact that adherent patients, on average, had higher baseline CCI scores. One might expect that patients with higher baseline CCI scores would be more likely to have higher medical utilization and costs. However, in our study, baseline CCI scores were higher in the adherent patients, giving credence to the theory that 5-ASA adherence may decrease utilization and costs despite the higher baseline CCI scores. Patients therefore were likely to benefit (i.e., have lower medical resource utilization) from adhering to their medication, regardless of their prior overall medical condition. Our study thus corroborates the findings of Kane[14] that nonadherence leads to higher cost of care. Increased medication costs among the adherent patients were more than offset by significant reductions in other cost sectors, such as inpatient costs, ER admission costs, outpatient physician and other visits, and nonpharmacy visit costs. Our results were consistent with the American Gastroenterological Association’s report on the burden of gastrointestinal diseases, which found pharmacy and inpatient costs to be the key cost driver in the overall burden of UC [2].

While our data source presents unique advantages in assessing medication adherence and associated outcomes, our study is subject to several limitations inherent in most analyses of retrospective claims data. Therapy may be interrupted for clinically appropriate reasons, such as side effects associated with 5-ASAs and abnormal laboratory results. If this occurred, the calculated MPR would underestimate actual adherence rates. We also assumed complete medication ingestion, but patients may have disposed of medication prior to refill or stockpiled medication for future use [29]. This would cause the MPR to overestimate actual adherence. Finally, some of the defined UC-related prescriptions could have been used for other indications. Despite these limitations, administrative claims data remain a reliable and well-accepted source for estimating adherence with chronic-use medications by using validated measures, such as the MPR [18,19,29,30]. Second, all UC patients were identified as such through the analysis of ICD-9-CM diagnosis codes that, if recorded inaccurately, may have caused some patients to be misclassified into the defined groups. The accuracy of our results therefore

---

**Table 3 Adjusted health care costs during 12-month period following 5-ASA initiation, by 5-ASA adherence status**

| Cost Outcome                              | Adherent                      | Not Adherent                   |
|-------------------------------------------|-------------------------------|--------------------------------|
|                                                                 | Mean Predicted Cost* | 95% Confidence Interval | Mean Predicted Cost* | 95% Confidence Interval | P Value |
| Cost of inpatient admissions              | $14,541.65                   | [$14,313.80, $14,769.49]   | $28,726.65           | [$28,443.11, $29,010.19] | <0.0001 |
| Cost of ER visits                         | $495.33                      | [$477.91, $512.76]         | $635.95              | [$621.95, $649.94]        | <0.0001 |
| Cost of outpatient office visits          | $1,081.83                    | [$1,046.79, $1,116.87]      | $1,145.67            | [$1,121.99, $1,169.35]    | 0.0031  |
| Cost of other outpatient/ ancillary visits| $3,702.39                    | [$3,602.08, $3,802.70]    | $4,923.29            | [$4,837.67, $5,008.91]   | <0.0001 |
| Cost of pharmacy prescriptions            | $5,309.84                    | [$5,180.82, $5,438.86]    | $3,189.88            | [$3,142.40, $3,237.35]   | <0.0001 |
| Cost of UC-related pharmacy prescriptions | $3,568.57                    | [$3,519.87, $3,617.27]   | $1,718.20            | [$1,702.68, $1,733.73]   | <0.0001 |
| Cost of non–UC-related pharmacy prescriptions | $1,845.51                    | [$1,746.93, $1,944.09]   | $1,541.60            | [$1,487.04, $1,596.17]   | <0.0001 |
| Cost of non-pharmacy visits               | $8,101.24                    | [$7,848.17, $8,354.30]   | $14,226.32           | [$13,936.79, $14,515.85] | <0.0001 |
| Cost of total visits                      | $13,464.89                   | [$13,094.43, $13,835.35]  | $17,339.36           | [$17,033.28, $17,645.45]  | <0.0001 |

5-ASA = 5-aminosalicylate; ER = emergency department; UC = ulcerative colitis.

*Predicted costs are based on generalized linear models and control for age, gender, geographic region, health plan type, payer type, and Charlson Comorbidity Index scores. Separate models were run for each cost sector; therefore, the mean predicted cost for each sector does not sum up to the total predicted cost.
depends on the accuracy of the data recorded in the LifeLink database. The impact of misclassification bias stemming from analyses of claims data has been described in previous research [31,32]. Third, in order to select patients with active UC, we required that patients have at least one corticosteroid prescription in the 12-month period following 5-ASA initiation. A possible confounder is that some patients might have stopped their 5-ASA therapy due to non-response or because they are more severe patients and moved on to corticosteroids, thereby appearing to be nonadherent to 5-ASAs, not because of nonadherent medication-taking behavior but for a clinically appropriate reason. If this hypothesis is true, we would expect corticosteroid use to be greater in the non-adherent group. We therefore examined the total number of prescriptions for corticosteroids over the 12-month follow-up period for the adherent and non-adherent groups and found the reverse to be true: the adherent group had more steroid prescriptions on average (4.1) compared to the non-adherent group (3.4), and stayed on steroids for a longer duration (88.6 vs. 67.9 days). This demonstrates that these patients are more adherent in general and are therefore more adherent to their corticosteroid prescriptions too. Therefore, it seems evident that higher severity, as measured by the use of corticosteroids in the non-adherent group is not an explanation for lower 5-ASA adherence in that group. Fourth, we did not have any data on important clinical factors such as treatment-related adverse events or disease severity, or demographic factors such as race and socioeconomic status, any of which could impact both medication adherence and health care resource utilization. We did however find no significant difference in the proportion of patients using other 5-ASA drugs such as immunosuppressants and antibiotics between the two study groups, indicating that the groups had similar disease severity. Fifth, our study did not control for pre-index resource utilization. It is possible that nonadherent patients had greater costs prior to 5-ASA initiation. Finally, our study focused only on direct all-cause costs to commercial third-party payers, and is not representative of other health care payers such as Medicare or Medicaid. Also, there are other indirect costs, such as lost wages and reduced workplace productivity, which must be assessed in order to gain an understanding of the complete societal impact of UC.

Conclusions
In conclusion, this study finds adherence to oral 5-ASAs to be suboptimal and that patients who are nonadherent to therapy have greater health care costs. Efforts to promote oral 5-ASA adherence in patients with UC may lead to cost-savings for third-party payers and other stakeholders.

Endnotes
At the request of the health services with which we worked, we have been asked to use this term to refer to our informants in order to ensure anonymity.

Competing interests
Debanjali Mitra and Keith L. Davis are employees of RTI Health Solutions, an independent contract research organization that received research funding from Shire for this study. Dr. Paul Hodgkins and Linnette Yen are employees of Shire and own stock in the company. Dr. Russell D. Cohen is employed at the University of Chicago Medical Center and serves as a consultant to Shire. The author(s) declare that they have no other competing interests.

Authors’ contributions
Debanjali Mitra, Dr. Paul Hodgkins, and Linnette Yen were the primary developers of the study design and contributed to analysis and interpretation of results as well to the development of this manuscript. As principal investigator, Debanjali Mitra had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Debanjali Mitra and Keith L. Davis led all statistical analyses. Debanjali Mitra also served as the primary writer in drafting the manuscript text and in interpreting the results. Dr. Russell D. Cohen provided medical and clinical advice to refine and validate the study, and he participated in the drafting of the manuscript. All authors read and approved the final manuscript.

Acknowledgements
Funding for this study was provided by Shire Development, Inc. The publication of this study’s results is not contingent on the sponsor’s approval or censorship of the manuscript.

Author details
1RTI Health Solutions, 3040 Cornwallis Road, Post Office Box 12194, Research Triangle Park, NC, 27709-2194, USA. 2Shire Development Inc, 725 Chesterbrook Boulevard, Chesterbrook, PA 19087, USA. 3The University of Chicago Medical Center, 5841 South Maryland Avenue, Chicago, IL 60637, USA.

Received: 6 December 2011 Accepted: 20 September 2012
Published: 24 September 2012

References
1. Loftus EV, Silverstein MD, Sandborn WJ, Tremaine W, Harmsen W, Zinsmeister A: Ulcerative colitis in Olmstead county, Minnesota, 1940–1993: incidence, prevalence, and survival. Gut 2000, 46:336–343.
2. American Gastroenterological Association: The burden of gastrointestinal diseases. 2001, www.learwin.com/content/publications/2695.pdf.
3. Kappelman MD, Rifas-Shiman SL, Porter CQ, Olendruf DA, Sandler RS, Galanko JA, Finkelstein JA: Direct health care costs of treatment of Crohn’s disease and ulcerative colitis in U.S. Children and adults. Gastroenterology 2008, 135:1907–1913.
4. Hickerson SL, Waters HC, Dabbous O, Tang BI, Rahman M: Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients. J Manag Care Pharm 2008, 14(4):352–362.
5. Sutherland L, Roth D, Beck P, May G, Malakyan K: Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, 2:CD000544.
6. Sutherland L, MacDonald JK: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, 3:CD000543.
7. Kornbluth A, Sachar DB: Practice parameters committee of the American college of gastroenterology: ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee. Am J Gastroenterol 2010, 105:501–523.
8. Gordin L: Conceptual and methodologic problems in measuring patient compliance. In Compliance in health care. Edited by Haynes RB, Sackett DL. Baltimore: Johns Hopkins University Press; 1979.
9. Haynes RB, Dantes R: Patient compliance and the conduct and interpretation of therapeutic trials. Control Clin Trials 1987, 8:12–19.
10. Kennedy S, McIntyre R, Fallu A, Lam R. Pharmacotherapy to sustain the fully remitted state. J Psychiatry Neurosci 2002, 27(4):269–280.

11. Breen R, Thomhill JT. Noncompliance adherence with medication for psychiatric disorders. CNS Drugs 1998, 9:457–471.

12. Yen L, Kingman D, Hodgkins P. Improved adherence and persistence with once-daily lialda® therapy for ulcerative colitis in the United States: retrospective analysis of a Multiplan claims database. Poster presented at American college of gastroenterology annual scientific meeting. San Antonio, Texas; 2010:18–20.

13. Shaya FT, El Khouy AC, Wong W, Whitelaw N, Whitelaw G, Joseph RE, Cohen RD. Persistence with pharmacotherapy for gastrointestinal disease: associated costs of health care. PBT 2006, 31:657–665.

14. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006, 23:577–585.

15. IMS LifeLink data on file: Systematic review: adherence issues in the treatment of ulcerative colitis.

16. Charlton ME, Pompei P, Ales KL, McKenzie CR.

17. Deyo RA, Cherkin DC, Ciol MA.

18. Andrade SE, Kahler KH, Frech MPH, Chan KA.

19. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC.

20. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Mov Discord 2005, 20(11):1502–1507.

21. Rosen ML, Rigsby MO, Salahi FT, Ryan CE, Cramer JA: Electronic monitoring and counseling to improve medication adherence. Behav Res Ther 2004, 42:409–422.

22. George CF, Peveler RC, Heiliger S, Thompson C. Compliance with tricyclic antidepressants: the value of four different methods of assessment. Br J Clin Pharmacol 2004, 50:166–171.

23. US Department of Labor, Bureau of Labor Statistics: Consumer price index—all urban consumers (current series). 2011. [http://data.bls.gov/PDQ/outside.jsp?survey=ca].

24. Basu A, Manning WG. Issues for the next generation of health care cost analyses. Med Care 2009, 47(7 Suppl 1):S109–S114.

25. Fu AZ, Qu Y, Radican L, Wells BJ. Health care and productivity costs associated with diabetic patients with macrovascular comorbid conditions. Diabetes Care 2009, 32(12):2187–2192. E-pub 2009 Sep 3.

26. Wedderburn RWJ. Quasi-likelihood functions, generalized linear models, and the gauss-Newton method. Biometrika 1974, 61:439–447.

27. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998, 17:283–295.

28. Manning WG, Mullany J. Estimating log models: to transform or not to transform? J Health Econ 2001, 20:461–494.

29. Sikka R, Xia F, Aubert RE. Estimating medication persistence using administrative claims data. Am J Manag Care 2005, 11(7):449–457.

30. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health 2009, 12(6):899–905.

31. Newcomer R, Clay T, Luxenberg JS, Miller RH. Misclassification and selection bias when identifying Alzheimer's disease solely from Medicare claims records. J Am Geriatr Soc 1999, 47(2):215–219.

32. Losina E, Barrett J, Baron JA, Katz JN. Accuracy of medicare claims data for rheumatologic diagnoses in total hip replacement recipients. J Clin Epidemiol 2003, 56:S15–S19.